EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Heart Rate Reduction Is Associated With Reverse Left Ventricular Remodeling and Mechanism-Specific Molecular Phenotypes in Dilated Cardiomyopathy

Natasha L Altman, Edward A Gill iD, Rami Kahwash iD, Leslie K Meyer iD, Jessica A Wagner, Anis Karimpour-Fard iD, Amber A Berning iD, Wayne A Minobe iD, Ian A Carroll iD, Eric R Jonas iD, Dobromir Slavov, Sitaramesh Emani und 10 weitere

Circulation: Heart Failure · 2025-04 · 18 (4)

DOI: 10.1161/circheartfailure.124.012484 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Circulation: Heart Failure, 2025-04. Verfasst von Natasha L Altman und 21 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology (N.L.A., E.A.G., L.K.M., J.A.W., A.K.-F., W.A.M., I.A.C., E.R.J., D.S., S.L.E., M.R.G.T., S.L.G., L.M., T.A.M., P.M.B., D.P.K.…. Hauptthemen laut MEDLINE: Cardiomyopathy, Dilated, Ventricular Remodeling, Heart Rate, Ventricular Function, Left. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: American Heart Association-American Stroke Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Heart rate (HR) affects heart failure outcomes, via uncertain mechanisms that may include left ventricular remodeling. However, in human ventricular myocardium, HR change has not been associated with a particular remodeling molecular phenotype. METHODS: Patients with nonischemic dilated cardiomyopathy (N=22) in sinus rhythm and refractory to β-blockade for both HR lowering and reverse remodeling were randomized 2:1 double-blind to the HCN4 (hyperpolarization-activated cyclic nucleotide–gated potassium channel 4) channel inhibitor ivabradine or placebo for 24 weeks treatment while maintaining target doses of β-blockers. Reverse remodeling was measured by left ventricular ejection fraction (LVEF), and myocardial gene expression by sequencing RNA extracted from endomyocardial biopsies. The primary statistical analysis was between HR change categories divided at the median, which resulted in Decreased HR (N=90) and Unchanged HR (N=8) groups. RESULTS: Respective HRs at baseline and 24 weeks were as follows: Decreased HR, 82.9±6.8 and 69.7±8.0 beats per minute ( P =0.0005) and Unchanged HR, 80.8±5.7 and 79.2±11.6 beats per minute ( P =0.58). All completing Decreased HR subjects were treated with ivabradine, whereas in the Unchanged HR group, 3 received ivabradine and 5 placebo. In Decreased HR, LVEF increased from 29.4±8.8% at baseline to 44.2±9.4% at 24 weeks ( P =0.0003), compared with respective values of 26.6±11.4% and 29.2±12.0% ( P =0.28) in Unchanged HR. HR and LVEF changes were not different from a previously conducted β-blocker nonischemic dilated cardiomyopathy study subdivided into LVEF responders and nonresponders. However, differentially expressed genes (N=151) in the Decreased versus Unchanged HR groups were >99% nonconcordant and therefore individually unique compared with β-blocker HR/LVEF responders versus nonresponders (2 shared differentially expressed genes). Multiple unique differentially expressed genes in Decreased HR including NRG1 upregulation are considered cardioprotective or involved in cardiac development. CONCLUSIONS: In patients with nonischemic dilated cardiomyopathy in sinus rhythm, HR lowering per se (1) is associated with substantial left ventricular reverse remodeling; (2) its absence can cause β-blocker reverse remodeling nonresponse; and (3) when from HCN4 channel inhibition, results in a unique molecular phenotype. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02973594.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiomyopathy, DilatedVentricular RemodelingHeart RateVentricular Function, LeftHumansMaleFemaleMiddle AgedDouble-Blind MethodIvabradinePhenotypeStroke VolumeAgedHyperpolarization-Activated Cyclic Nucleotide-Gated ChannelsAdrenergic beta-AntagonistsTreatment OutcomeCardiovascular AgentsMuscle ProteinsPotassium Channels

Stichwörter der Autor:innen

cardiomyopathy, dilatedgene expressionheart failureheart rateivabradineneuregulin-1ventricular remodeling

Substanzen

IvabradineHyperpolarization-Activated Cyclic Nucleotide-Gated ChannelsAdrenergic beta-AntagonistsCardiovascular AgentsHCN4 protein, humanMuscle ProteinsPotassium Channels

Autor:innen und Institutionen

  • Division of Cardiology (N.L.A., E.A.G., L.K.M., J.A.W., A.K.-F., W.A.M., I.A.C., E.R.J., D.S., S.L.E., M.R.G.T., S.L.G., L.M., T.A.M., P.M.B., D.P.K., M.R.B.), University of Colorado Anschutz Medical Campus, Aurora.
  • Division of Cardiology, The Ohio State University Wexner Medical Center, Columbus (R.K., S.E., W.T.A., A.R.G.).
  • Department of Pathology (A.A.B.), University of Colorado Anschutz Medical Campus, Aurora.
  • Genvara Biopharma, Westminster, CO (I.A.C., M.R.B.).

ORCID-Profile: Edward A Gill, Rami Kahwash, Leslie K Meyer, Anis Karimpour-Fard, Amber A Berning, Wayne A Minobe, Ian A Carroll, Eric R Jonas, William T Abraham, Matthew R G Taylor, Luisa Mestroni, Timothy A McKinsey, Peter M Buttrick, David P Kao, Michael R Bristow

Förderung

  • American Heart Association-American Stroke Association

Zitieren

APA

Altman, N. L., Gill, E. A., Kahwash, R., Meyer, L. K., Wagner, J. A., Karimpour-Fard, A., Berning, A. A., Minobe, W. A., Carroll, I. A., Jonas, E. R., Slavov, D., Emani, S., Abraham, W. T., Gollah, A. R., Ellis, S. L., Taylor, M. R. G., Graw, S. L., Mestroni, L., McKinsey, T. A., …, & Bristow, M. R. (2025). Heart Rate Reduction Is Associated With Reverse Left Ventricular Remodeling and Mechanism-Specific Molecular Phenotypes in Dilated Cardiomyopathy. Circulation: Heart Failure, 18(4). https://doi.org/10.1161/circheartfailure.124.012484

Vancouver

Altman NL, Gill EA, Kahwash R, Meyer LK, Wagner JA, Karimpour-Fard A, et al. Heart Rate Reduction Is Associated With Reverse Left Ventricular Remodeling and Mechanism-Specific Molecular Phenotypes in Dilated Cardiomyopathy. Circulation: Heart Failure. 2025;18(4). doi:10.1161/circheartfailure.124.012484

BibTeX
@article{Altman2025,
  author = {Altman, Natasha L and Gill, Edward A and Kahwash, Rami and Meyer, Leslie K and Wagner, Jessica A and Karimpour-Fard, Anis and Berning, Amber A and Minobe, Wayne A and Carroll, Ian A and Jonas, Eric R and Slavov, Dobromir and Emani, Sitaramesh and Abraham, William T and Gollah, Alexa R and Ellis, Samuel L and Taylor, Matthew R G and Graw, Sharon L and Mestroni, Luisa and McKinsey, Timothy A and Buttrick, Peter M and Kao, David P and Bristow, Michael R},
  title = {Heart Rate Reduction Is Associated With Reverse Left Ventricular Remodeling and Mechanism-Specific Molecular Phenotypes in Dilated Cardiomyopathy},
  journal = {Circulation: Heart Failure},
  year = {2025},
  volume = {18},
  number = {4},
  doi = {10.1161/circheartfailure.124.012484}
}
Kostenlos starten →